Dynavox Group ABTDVXF -3.17%89 ROE % is 23.99% as of Mar. 2026, which is 38% below its 10-year median of 38.80. GuruFocus rates TDVXF with a GF Score™ of 89/100 and a GF Value™ of $8.94 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 796 Medical Devices & Instruments companies, Dynavox Group AB ranks better than 96.86% on this metric.
The historical rank and industry rank for Dynavox Group AB's ROE % or its related term are showing as below:
TDVXF'
s ROE % Range Over the Past 10 Years
Min: 27.76 Med: 38.8 Max: 441.5
Current: 33.01
During the past 7 years, Dynavox Group AB's highest ROE % was 441.50%. The lowest was 27.76%. And the median was 38.80%.
TDVXF's ROE % is ranked better than 96.86% of 796
companies
in the Medical Devices & Instruments industry
Industry Median: 2.45
vs TDVXF: 33.01
Dynavox Group AB (OTCPK:TDVXF) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Dynavox Group AB ROE % Related Terms
Dynavox Group AB ROE % Historical Data
* Premium members only.
The historical data trend for Dynavox Group AB's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Dynavox Group AB's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dynavox Group AB ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Dynavox Group AB's ROE % distribution charts can be found below:
* The bar in red indicates where Dynavox Group AB's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Dynavox Group AB (TDVXF) has a ROE % of 23.99% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Dynavox Group AB and its competitors. This is 38% below median its historical median of 38.80. Over the past decade, Dynavox Group AB's ROE % has ranged from 27.76 to 441.50. According to the industry distribution chart, Dynavox Group AB ranks #25 out of 796 companies in the Medical Devices & Instruments industry, placing it in the top 3.1%.
Is Dynavox Group AB's ROE % too high?
Dynavox Group AB's current ROE % of 23.99% is 38% below median its 10-year median of 38.80. Over the past 10 years, this metric has ranged from a low of 27.76 to a high of 441.50. The Medical Devices & Instruments industry median ROE % is 2.45. Dynavox Group AB's value of 23.99% is 879.2% above this industry median. Based on the distribution chart, Dynavox Group AB ranks #25 out of 796 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Dynavox Group AB has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Dynavox Group AB's ROE % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Dynavox Group AB ranks #25 out of 796 companies for ROE %. This places Dynavox Group AB in the top 3% of its industry — outperforming the majority of peers. The industry median ROE % is 2.45. Dynavox Group AB's value of 23.99% is 879.2% above this benchmark. Historically, Dynavox Group AB's own ROE % has ranged from 27.76 to 441.50 over the past decade. While the company's 10-year median is 38.80 vs. the industry median of 2.45, Dynavox Group AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.45, based on 796 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dynavox Group AB's current ROE % of 23.99% is 879.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Dynavox Group AB and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dynavox Group AB's current ROE % is 23.99%, which is 38% below median its own 10-year median of 38.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dynavox Group AB stock overvalued right now?
Based on GuruFocus' analysis, Dynavox Group AB (TDVXF) is currently considered Modestly Undervalued. The stock's GF Value™ is $8.94, compared to a current price of $6.57 — trading 26.5% below its estimated fair value. The current ROE % is 23.99%, which is 38% below median its 10-year median of 38.80 and 879.2% above the Medical Devices & Instruments industry median of 2.45. Dynavox Group AB's overall GF Score™ is 89/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Dynavox Group AB (TDVXF), the current ROE % is 23.99% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dynavox Group AB (TDVXF) Overvalued in 2026?
Based on GuruFocus' analysis, Dynavox Group AB stock appears to be undervalued.
The current stock price of $6.57 is trading 26.5% below its estimated GF Value™ of $8.94.
GuruFocus considers Dynavox Group AB to be Modestly Undervalued.
Key valuation signals for TDVXF:
ROE %: 23.99% (38% below median its 10-year median of 38.80)
GF Value™: $8.94 vs. price of $6.57 (26.5% below fair value)
Industry Position: 879.2% above the Medical Devices & Instruments median (#25 of 796)
No single metric tells the full story. See the TDVXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dynavox Group AB is engaged in assistive technology for communication. The company's Augmentative and Alternative Communication (AAC) solutions enable people with disabilities such as cerebral palsy, ALS, and spinal cord injury to communicate with a voice of their own, develop literacy skills, and live more independently. The company is a comprehensive SaaS provider with local roots. The company operates in Europe, North America, and Other countries, with the majority of revenue from North America.
89GF Score
Get the complete analysis for TDVXF
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TDVXF has been successfully added to your 
